AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
This research is looking to find out if the combination of Ipatasertib with Aromatase
inhibitor or Fulvestrant can be an effective treatment for breast cancer.